Stock·NASDAQ·Healthcare
CRISPR Therapeutics AG (CRSP)
- Market cap
- $4.98B
- Dividend yield
- None
- Street target
- $80.00median of 23 analysts
- 52-week range
- $44.12 $65.98
CRSP stock forecast today
Where CRSP stands today, and what CleaRank Financial AI makes of it.
CRSP at a glance
CRISPR Therapeutics AG (CRSP): Hold, 45/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($54.41 and $52.92).
- Earnings CRSP beat estimates in 2 of the 4 reports in our data, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $21.7M and bought $52.6M over the last 18 months.
Figures as of October 27, 2026.
CleaRank Financial AI
CleaRank rates CRISPR Therapeutics AG (CRSP) Hold with a model score of 45/100.
The analysts' outlook is the biggest contributor: 13 of 23 analysts rate the stock a buy and the median target is 55.4% above the price. Valuation is the largest drag, since the company has no meaningful P/E after losing money and its P/S of 371.62 is 10,830.0% above the sector median. The trend leans down, with the price 5.41% below its 50-day average of $54.41 and 2.75% below its 200-day average of $52.92. Across the past year, the price dropped 21.68%.
Only on CleaRank
Figures we compute ourselves from CRSP's own price, earnings and insider-filing history. Tap one to see it in context.
CRSP stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
1/4Price above its 50-day average ›
The price of $51.47 is 5.4% below the 50-day simple moving average of $54.41.Price above its 200-day average ›
The price is 2.7% below the 200-day simple moving average of $52.92.50-day average above the 200-day ›
The 50-day average ($54.41) is 2.8% above the 200-day average ($52.92), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 34% of its 52-week range, between $44.12 and $65.98.
CRSP share price
Pick a period: each tab shows how far CRSP has moved over it, to the last close.
Today's trading
Where CRSP sits inside today's range and its 52-week range.
CRSP fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
0/3P/S below the sector median ›
The price-to-sales ratio of 371.62 is 10,830.1% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was -$451.1M on revenue of $13.4M, a net margin of -3,368.7%.Beat estimates in most recent reports ›
CRSP beat the EPS estimate in 2 of the 4 reports in our data.
Key statistics
The headline figures for CRSP.
As of October 27, 2026, CRSP trades at $51.47, with a market value of $4.98B and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of CRSP's valuation, growth and risks.
A P/E cannot be read for CRSP: it is not meaningful, because its earnings per share over the last 12 months are negative. CRSP trades at 371.62 times its sales, 10,830.0% above the sector median of 3.4. CRSP has a market capitalisation of $5.0B.
CRSP is unprofitable: its net margin stands at -3,368.72% and its operating margin at -1,127.55%. Revenue growth of 1,041.40% puts it 1,033.3 percentage points faster than the sector median of 8.1%. Return on equity of -26.10% is below the sector median of 7.3%, and debt-to-equity of 0.45 completes the balance sheet picture.
CRSP's most recent available report in our data, dated May 4, 2026, delivered EPS of -$1.28, short of the estimate of -$1.23, so it was a weaker result than analysts had forecast. The share price dropped 2.24% in the first session after the report.
CRSP beat estimates in 2 of the 4 reports in our data, but the stock still declined in the first session after 1 of those 2 beats. Further back, the shares dropped 6.71% following the August 4, 2025 report, which beat the estimate by 7.86%. Analysts expect EPS of -$4.45 this fiscal year and -$3.55 next year.
The price of CRSP typically moves by 3.43% a day, measured as the 30-day standard deviation of its daily returns, and its beta against the S&P 500 is 1.76. Holders face a headwind while the price remains beneath its moving averages. The price is 21.99% under its 52-week high of $65.98. Over the last 18 months insiders sold $21.7M of stock and bought $52.6M; these sales are often planned in advance, so they tell less than purchases would.
CRSP against the Healthcare sector
How CRSP compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, CRSP trades at 371.62x, far above the sector average of 3.40x.
Return vs XLV: Since May 15, 2025, CRSP has gained 41.8% against a gain of 37.3% for XLV.
Performance against XLV
CRSP and the Healthcare sector fund over the same days.
Revenue and earnings
How much CRSP sells, and how much of it becomes profit.
Revenue growth: Revenue fell 90.5% in FY2024 to $35.0M, from $370M a year earlier.
Profit margin: The net margin was -1,046.4% in FY2024, down from -41.5% the year before.
Loss-making: CRSP lost $366M in FY2024.
Earnings reality check
Did CRSP beat what analysts expected, and how did the stock react?
Earnings record: CRSP beat the analyst estimate in 2 of the 4 reports in our data.
Market reaction: The stock fell in the first session after 1 of those 2 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| May 4, 2026after close | -$1.23 | -$1.28 | -4.07% | -2.24% | +0.80% |
| Nov 10, 2025after close | -$1.29 | -$1.17 | +9.30% | +1.15% | +1.36% |
| Aug 4, 2025after close | -$1.40 | -$1.29 | +7.86% | -6.71% | -7.01% |
| May 6, 2025after close | -$1.28 | -$1.58 | -23.44% | +3.29% | +12.24% |
Reports after May 4, 2026 are not yet in our data.
As of October 27, 2026, CRSP has beaten the analyst EPS estimate in 2 of the 4 reports in our data and fell in the first trading session after 1 of those beats; its most recent report in our data, on May 4, 2026, came in 4.07% below the estimate and the stock moved -2.24% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
CRSP AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 48.2, in neutral territory.RSI above 50 ›
An RSI of 48.2 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank Financial AI analysis of CRSP
The score, the reasoning behind it, and what could move the price next.
CRSP is in a downtrend: the price of $51.47 sits 2.75% below its 200-day average of $52.92 and 5.41% below its 50-day average of $54.41. The shorter average still lies 2.81% above the 200-day, but the price has already dropped beneath it. Measured across its 52-week range from $44.12 to $65.98, the price stands at 34%, and it is 21.99% below the high.
The short and long run point different ways: the price fell 5.09% over the past month, rose 8.24% over the past three months and fell 21.68% over the past year. The 14-day RSI of 48.2 is in the neutral zone, and the MACD line is negative.
Earnings miss ›
The May 4, 2026 report missed the EPS estimate by 4.07%, and the share price fell 2.24% in the first session after it.
Source: Earnings report, May 4, 2026
New analyst coverage ›
UBS started coverage at Neutral on October 15, 2026.
Source: Analyst action, UBS, October 15, 2026
- The two levels closest to CRSP's price are the 200-day SMA at $52.92, above the price, and the 52-week low at $44.12, below it.
- A 14-day RSI of 48.2 is neutral, and the MACD line is negative. Readings above 70 or below 30 would signal stretched momentum in either direction.
- CRSP's share price dropped 2.24% in the first session after the May 4, 2026 report, and the company has beaten estimates in 2 of the 4 reports in our data.
CRSP sits right at its 20-day EMA, but the broader picture is weaker. The stock trades under both its 50-day average of $54.41 and its 200-day average of $52.92, and that combination is why the trend reads down. A recovery above the 200-day would be the first sign of repair, and that average at $52.92 is the next level above the price.
The next level below the price for CRSP is the 52-week low at $44.12.
Technical indicators
Momentum and trend for CRSP, from its daily closes.
As of October 27, 2026, with CRSP at $51.47, its 14-day RSI is 48.2 (neutral territory), its 50-day simple moving average is $54.41 and its 200-day is $52.92.
Calculated by CleaRank on daily closes as of October 27, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What CRSP moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 27, 2026, CRSP's 1-year correlation of daily returns is +0.40 with S&P 500 (SPY), +0.39 with Nasdaq 100 (QQQ), +0.34 with Bitcoin (BTC) and +0.21 with gold (XAU).
CRSP price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
13 of 23 analysts rate it a buy or strong buy, 10 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $80.00 is 55.4% above the price.More buy ratings than three months ago ›
13 of 23 rate it a buy now, against 13 of 22 three months ago.
CRSP Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 15, 2026 | UBS | Initiates | Neutral |
| Aug 31, 2026 | Citizens | Reiterates | Market Outperform |
| Aug 31, 2026 | Needham | Reiterates | Buy |
| Aug 25, 2026 | Citizens | Reiterates | Market Outperform |
| Aug 4, 2026 | Citigroup | Maintains | Buy |
| Jul 8, 2026 | HC Wainwright & Co. | Reiterates | Buy |
As of October 27, 2026, 23 Wall Street analysts cover CRSP: 13 rate it a buy or strong buy, 10 a hold and 0 a sell or strong sell. Their 12-month price targets range from $44.00 to $291.00. The median CRSP price target is $80.00, 55.4% above the price of $51.47.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
CRSP trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
CRSP trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
CRSP moves about 3.4% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much CRSP tends to move, against the market and on its own.
CRSP price history and drawdowns
CRSP's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move under 2% ›
The price has moved 3.43% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 84.4%, from January 2021 to April 2025; the price is still 74.2% below that peak.Most 1-year holds ended higher ›
55% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $30,747, against $42,376 in the S&P 500 (SPY).
CRSP Drawdowns & Recovery
As of October 27, 2026, CRSP's worst peak-to-trough fall over the last 10 years with dividends reinvested was -84.4% (January 2021 to April 2025); it is still 74.2% below that peak, and 55% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into CRSP in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: CRSP trailed the S&P 500 over this period: $30,747 against $42,376.
A $10,000 investment in CRSP in October 2016 would be worth about $30,747 today with dividends reinvested, compared with about $42,376 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to CRSP, and which have not.
Strongest month, November: an average of +13.70%, up in 7 of 10 years.
Weakest month, March: an average of -6.47%, up in 3 of 10 years.
This month, October: has averaged -4.20%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, CRSP's strongest calendar month has been November (average +13.70%, up in 7 of 10 years) and its weakest March (average -6.47%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
CRSP stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in CRSP, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in CRSP today could grow to about $13,794 by 2030 in the base case, with a 90th-percentile outcome near $49,692 and a 10th-percentile outcome around $3,829. Projections are statistical simulations, not guarantees.
CRSP Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $71.00 for CRSP by 2030 in the base case, from $51.47 today (1.4x over 4 years). The 10th-percentile path ends near $19.71. These are outcomes of a Monte Carlo simulation run on CRSP's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $29.39 | $55.78 | $106 | |
| 2028 | $24.42 | $60.45 | $150 | |
| 2029 | $21.59 | $65.51 | $199 | |
| 2030 | $19.71 | $71.00 | $256 |
Method: a lognormal simulation of CRSP's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
CRSP insider trading
What the people running the company have bought and sold.
CRSP insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider buying: Insiders bought $52.6M on the open market and sold $21.7M.
As of October 27, 2026, CRSP insiders reported 25 open-market sales worth $21.7M and 2 open-market purchases worth $52.6M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 19, 2026 | Samarth Kulkarni
Chief Executive Officer
|
Sell | 47.8K | $2.4M |
| Oct 16, 2026 | Samarth Kulkarni
Chief Executive Officer
|
Grant | 100.0K | - |
| Oct 6, 2026 | James R. Kasinger
General Counsel
|
Sell | 2.0K | $119.5K |
| Oct 6, 2026 | James R. Kasinger
General Counsel
|
Option | 2.0K | $27.1K |
| Sep 22, 2026 | James R. Kasinger
General Counsel
|
Sell | 10.4K | $626.5K |
| Sep 22, 2026 | James R. Kasinger
General Counsel
|
Option | 10.4K | $141.6K |
| Sep 17, 2026 | Ali Behbahani
Director
|
Sell | 13.7K | $780.9K |
| Sep 17, 2026 | Ali Behbahani
Director
|
Option | 30.0K | $420.0K |
| Aug 7, 2026 | Raju Prasad
Chief Financial Officer
|
Grant | 750 | - |
| May 29, 2026 | Naimish Patel
Officer
|
Sell | 3.8K | $210.6K |
| May 28, 2026 | Naimish Patel
Officer
|
Grant | 10.0K | - |
| Mar 23, 2026 | Samarth Kulkarni
Chief Executive Officer
|
Sell | 10.0K | $468.7K |
| Mar 23, 2026 | Raju Prasad
Chief Financial Officer
|
Sell | 3.7K | $173.5K |
| Mar 23, 2026 | James R. Kasinger
General Counsel
|
Sell | 3.2K | $148.9K |
| Mar 20, 2026 | James R. Kasinger
General Counsel
|
Grant | 6.3K | - |
| Mar 20, 2026 | Samarth Kulkarni
Chief Executive Officer
|
Grant | 19.7K | - |
| Mar 20, 2026 | Raju Prasad
Chief Financial Officer
|
Grant | 6.3K | - |
| Mar 16, 2026 | Samarth Kulkarni
Chief Executive Officer
|
Sell | 10.3K | $499.4K |
| Mar 16, 2026 | Raju Prasad
Chief Financial Officer
|
Sell | 9.9K | $476.3K |
| Mar 16, 2026 | James R. Kasinger
General Counsel
|
Sell | 3.5K | $166.5K |
| Mar 16, 2026 | Naimish Patel
Officer
|
Sell | 3.2K | $152.0K |
| Mar 16, 2026 | Raju Prasad
Chief Financial Officer
|
Grant | 750 | - |
| Mar 13, 2026 | James R. Kasinger
General Counsel
|
Grant | 6.9K | - |
| Mar 13, 2026 | Samarth Kulkarni
Chief Executive Officer
|
Grant | 20.6K | - |
| Mar 13, 2026 | Naimish Patel
Officer
|
Grant | 8.1K | - |
| Mar 13, 2026 | Raju Prasad
Chief Financial Officer
|
Grant | 16.9K | - |
| Mar 11, 2026 | Samarth Kulkarni
Chief Executive Officer
|
Sell | 9.8K | $517.3K |
| Mar 11, 2026 | James R. Kasinger
General Counsel
|
Sell | 2.8K | $147.8K |
| Mar 10, 2026 | James R. Kasinger
General Counsel
|
Grant | 5.5K | - |
| Mar 10, 2026 | Samarth Kulkarni
Chief Executive Officer
|
Grant | 19.3K | - |
| Feb 19, 2026 | Samarth Kulkarni
Chief Executive Officer
|
Sell | 7.0K | $366.3K |
| Feb 19, 2026 | James R. Kasinger
General Counsel
|
Sell | 2.1K | $111.0K |
| Feb 18, 2026 | James R. Kasinger
General Counsel
|
Grant | 3.8K | - |
| Feb 18, 2026 | Samarth Kulkarni
Chief Executive Officer
|
Grant | 13.3K | - |
| Jan 22, 2026 | Samarth Kulkarni
Chief Executive Officer
|
Sell | 90.0K | $5.2M |
| Jan 22, 2026 | Raju Prasad
Chief Financial Officer
|
Sell | 35.0K | $2.1M |
| Jan 22, 2026 | Raju Prasad
Chief Financial Officer
|
Option | 35.0K | $1.6M |
| Jan 6, 2026 | Raju Prasad
Chief Financial Officer
|
Sell | 29.7K | $1.8M |
| Jan 6, 2026 | Raju Prasad
Chief Financial Officer
|
Option | 29.7K | $1.3M |
| Dec 22, 2025 | Raju Prasad
Chief Financial Officer
|
Sell | 10.0K | $559.5K |
| Dec 18, 2025 | Samarth Kulkarni
Chief Executive Officer
|
Grant | 30.0K | - |
| Oct 17, 2025 | Samarth Kulkarni
Chief Executive Officer
|
Sell | 50.9K | $3.5M |
| Oct 16, 2025 | Samarth Kulkarni
Chief Executive Officer
|
Grant | 100.0K | - |
| Oct 14, 2025 | Samarth Kulkarni
Chief Executive Officer
|
Sell | 4.2K | $282.5K |
| Oct 14, 2025 | James R. Kasinger
General Counsel
|
Sell | 1.1K | $71.7K |
| Oct 13, 2025 | James R. Kasinger
General Counsel
|
Grant | 2.1K | - |
| Oct 13, 2025 | Samarth Kulkarni
Chief Executive Officer
|
Grant | 8.3K | - |
| Sep 17, 2025 | Samarth Kulkarni
Chief Executive Officer
|
Grant | 6.0K | - |
| Aug 18, 2025 | Samarth Kulkarni
Chief Executive Officer
|
Sell | 13.1K | $760.7K |
| Aug 15, 2025 | Samarth Kulkarni
Chief Executive Officer
|
Grant | 25.0K | - |
| Aug 6, 2025 | Douglas A Treco
Director
|
Buy | 20.0K | $1.1M |
| Jul 16, 2025 | Simeon J. George
Director
|
Buy | 989.8K | $51.5M |
| May 29, 2025 | Naimish Patel, M.D.
Officer
|
Sell | 3.9K | $141.3K |
| May 28, 2025 | Naimish Patel, M.D.
Officer
|
Grant | 10.0K | - |
Source: TwelveData, from reported insider filings
CRSP stock forecast: questions people ask
Answered from the figures on this page, as of October 27, 2026.